Telix Pharmaceuticals Limited
ASX: TLX
Telix Delivers Record Growth with Expanding Radiopharma Pipeline
(Source: TradingView) 3-Month Performance Profile of TLX on a DTF compared to ASX 200 (XJO)
Telix Pharmaceuticals (ASX: TLX) continues its strong momentum with Q3 2025 revenue at US$206 million, driving a robust year-to-date total and prompting management to raise FY 2025 guidance to US$800–820
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
